Aimovig (erenumab-aooe) / Amgen, Novartis 
Welcome,         Profile    Billing    Logout  
 12 Diseases   17 Trials   17 Trials   2487 News 


«12...4567891011121314...2425»
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    P3 data, Journal:  Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials. (Pubmed Central) -  Mar 11, 2022   
    The MFIQ measures the frequency of impacts and level of difficulty on multiple functional domains that provide a more complete picture of the effects of migraine. MFIQ scores showed that in comparison with placebo, patients treated with erenumab had greater reductions in the functional impact of migraine, providing insight into treatment benefits that extend beyond improvements in clinical status and health-related quality of life previously reported based on clinical end points and other PROs.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Comparative Cost-Effectiveness and Cost-Utility Analyses of Erenumab and Topiramate for the Prophylaxis of Patients with Episodic Migraine (Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1580;    
    ClinicalTrials.gov Identifiers: NCT01952574, NCT02456740, NCT02483585, NTCT02066415, and NCT02174861. In terms of cost-effectiveness, the treatment with subcutaneous Erenumab at 70-140 mg/month was dominated by oral topiramate at 50-100 mg/day; notwithstanding, in terms of utility, Erenumab provided on average nearly four months of Quality of Life to patients with EM, although its cost-utility ratio would require a better price to make it a favorable option for Colombian Health System.
  • ||||||||||  Chantix (varenicline) / Pfizer, Aimovig (erenumab) / Amgen, Novartis
    The Relative Value of Anti-Obesity Medications Compared to Similar Therapies (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_155;    
    Obesity was associated with the costliest comorbidities and weight loss had the largest medical cost savings. Despite this, AOMs are not currently covered by most health plans.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Effect of Erenumab on Patient-Reported Outcomes in Patients With Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study (Poster Hall) -  Mar 6, 2022 - Abstract #AAN2022AAN_3446;    
    P3
    The results of this post-hoc analysis complement the superior efficacy results of erenumab compared with topiramate from the analysis of HER-MES primary results. In line with pivotal studies, this analysis of the EMPOwER study showed favorable treatment effects of erenumab (70mg and 140mg) versus placebo on the physical functioning and other aspects of daily activities impacted by headache as assessed by selected PRO scales in patients with episodic migraine.
  • ||||||||||  Retrospective data, Review, Journal:  Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. (Pubmed Central) -  Mar 5, 2022   
    Rimegepant, atogepant, and mAbs were all effective treatment options for the prevention of migraine when compared vs placebo and generally showed similar effects when compared to one another. Although all doses of anti-CGRP mAbs have comparable efficacy, safety and tolerability based on uncertainties in indirect comparisons for all outcomes, the calculated effect estimates numerically favored high doses of subcutaneous fremanezumab and intravenous eptinezumab as the effective therapy with acceptable safety and tolerability for short term prevention of chronic migraine.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  EMBRACE: Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (clinicaltrials.gov) -  Feb 25, 2022   
    P4,  N=576, Recruiting, 
    At least in part, migraine and sleep share common anatomic structures, neural pathways and signaling neurotransmitters. Trial completion date: Apr 2023 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Jul 2024
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial termination, Trial primary completion date:  AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) -  Feb 23, 2022   
    P1,  N=52, Terminated, 
    Trial completion date: Apr 2023 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Jul 2024 Trial completion date: Jun 2022 --> Nov 2021 | Recruiting --> Terminated | Trial primary completion date: Apr 2022 --> Nov 2021
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Retrospective data, Journal, Real-world evidence:  Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study. (Pubmed Central) -  Feb 22, 2022   
    The majority of patients prescribed erenumab remained persistent for at least a year after treatment initiation, and most patients initiated or escalated to a 140 mg dose. These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real-world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Study of Intravenous Erenumab in Patients With Status Migrainosus (clinicaltrials.gov) -  Feb 22, 2022   
    P1,  N=0, Withdrawn, 
    These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real-world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available. N=15 --> 0 | Trial completion date: Nov 2022 --> Feb 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Feb 2022
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial initiation date:  Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI (clinicaltrials.gov) -  Feb 16, 2022   
    P2,  N=404, Not yet recruiting, 
    N=15 --> 0 | Trial completion date: Nov 2022 --> Feb 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Feb 2022 Initiation date: Oct 2021 --> Feb 2022
  • ||||||||||  Journal:  New Anti-CGRP Medications in the Treatment of Vestibular Migraine. (Pubmed Central) -  Feb 15, 2022   
    Results demonstrated a trend toward improvement, suggesting that the CGRP medications appear to be a decent treatment option for VM. A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option.
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Clinical, Journal:  Timing and durability of response to erenumab in patients with episodic migraine. (Pubmed Central) -  Feb 10, 2022   
    A prospective study evaluating CGRP medications in patients with VM would provide further information about this treatment option. These results support guidelines recommending at least 3 months following the initiation of erenumab for migraine prevention before the assessment of response.
  • ||||||||||  Retrospective data, Journal:  Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine. (Pubmed Central) -  Feb 9, 2022   
    Network meta-analysis results suggested that in the comparison of the average migraine days per month, Erenumab  (140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) were superior to placebo, Erenumab(7 mg), and the difference was statistically significant; Fremanezumab (225 mg, 675 mg) was superior to Erenumab (21 mg, 70 mg), and the difference was statistically significant; in the comparison of average medication days of acute migraine-specific drug per month, Erenumab (70 mg, 140 mg), Galcanezumab (120 mg, 240 mg), Fremanezumab (225 mg, 675 mg) was superior to placebo, and Erenumab (140 mg) and Galcanezumab (120 mg, 240 mg) were superior to Erenumab (70 mg), and the difference was statistically significant; there was no statistically significant difference in the average migraine days in the last month or in the medication days of acute migraine-specific drug. Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocol after a comprehensive assessment.
  • ||||||||||  Qulipta (atogepant) / AbbVie
    Journal:  Atogepant (Qulipta) for migraine prevention. (Pubmed Central) -  Feb 8, 2022   
    Fremanezumab (225 mg) and Galcanezumab (120 mg) may be the best clinical protocol after a comprehensive assessment. No abstract available
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Journal:  Erenumab for the treatment of chronic resistant migraine. (Pubmed Central) -  Feb 3, 2022   
    The diversity of endpoint determination and the heterogeneity between studies for some endpoints cause some limitations for this study. No abstract available
  • ||||||||||  Aimovig (erenumab) / Amgen, Novartis
    Clinical, Journal:  Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. (Pubmed Central) -  Jan 28, 2022   
    We therefore conclude that the constipation elicited by antibodies targeting CGRP or its receptor results from interference with the physiological function of CGRP in the small and large intestine in which it contributes to the maintenance of peristaltic motor activity, ion and water secretion and intestinal transit. Erenumab reduced significantly migraine frequency and pain medication intake in refractory chronic migraine with MOH patients.